Journal
MOLECULAR ONCOLOGY
Volume 14, Issue 3, Pages 520-538Publisher
WILEY
DOI: 10.1002/1878-0261.12632
Keywords
bioinformatics; brain metastasis; breast cancer; microRNAs; myocyte enhancer factor 2C; next-generation sequencing
Categories
Funding
- Portuguese Foundation for Science and Technology (FCT), Portugal [PTDC/MED-ONC/29402/2017, PPBI-POCI-01-0145-FEDER-022122, 441.00 HUNGRIA, UID/DTP/04138/2019]
- National Research, Development and Innovation Office (NKFIH, Hungary) [FK-124114, K-116158, TET_16-1-2016-0079, GINOP-2.3.2-15-2016-00020, GINOP-2.3.2-15-2016-00034]
- Executive Unit for Financing Higher Education, Research, Development and Innovation (UEFISCDI, Romania) [PN-III-P1-1.1-TE-2016-1352, PN-III-P4-ID-PCE-2016-0408]
- Janos Bolyai Research Fellowship of the Hungarian Academy of Sciences [BO/00334/16/8]
- Fundação para a Ciência e a Tecnologia [PTDC/MED-ONC/29402/2017] Funding Source: FCT
Ask authors/readers for more resources
Breast cancer brain metastases (BCBMs) have been underinvestigated despite their high incidence and poor outcome. MicroRNAs (miRNAs), and particularly circulating miRNAs, regulate multiple cellular functions, and their deregulation has been reported in different types of cancer and metastasis. However, their signature in plasma along brain metastasis development and their relevant targets remain undetermined. Here, we used a mouse model of BCBM and next-generation sequencing (NGS) to establish the alterations in circulating miRNAs during brain metastasis formation and development. We further performed bioinformatics analysis to identify their targets with relevance in the metastatic process. We additionally analyzed human resected brain metastasis samples of breast cancer patients for target expression validation. Breast cancer cells were injected in the carotid artery of mice to preferentially induce metastasis in the brain, and samples were collected at different timepoints (5 h, 3, 7, and 10 days) to follow metastasis development in the brain and in peripheral organs. Metastases were detected from 7 days onwards, mainly in the brain. NGS revealed a deregulation of circulating miRNA profile during BCBM progression, rising from 18% at 3 days to 30% at 10 days following malignant cells' injection. Work was focused on those altered prior to metastasis detection, among which were miR-802-5p and miR-194-5p, whose downregulation was validated by qPCR. Using targetscan and diana tools, the transcription factor myocyte enhancer factor 2C (MEF2C) was identified as a target for both miRNAs, and its expression was increasingly observed in malignant cells along brain metastasis development. Its upregulation was also observed in peritumoral astrocytes pointing to a role of MEF2C in the crosstalk between tumor cells and astrocytes. MEF2C expression was also observed in human BCBM, validating the observation in mouse. Collectively, downregulation of circulating miR-802-5p and miR-194-5p appears as a precocious event in BCBM and MEF2C emerges as a new player in brain metastasis development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available